Both in Pharmaceuticals
PTC Therapeutics vs Erasca
Over the past year PTCT returned +0.3% and ERAS returned +515.1%; their daily moves had a correlation of 0.10.
PTCT +0.3% ERAS +515.1%Growth of $1, one year, split-adjusted
| Metric | PTCT | ERAS |
|---|---|---|
| Price | $68.12 | $14.64 |
| Market cap | $5.69B | $5.12B |
| Today | +11.89% | +4.20% |
| 1 month | +7.0% | −0.5% |
| 6 months | +4.7% | +46.5% |
| Year to date | −10.3% | +293.5% |
| 1 year | −0.3% | +505.0% |
| Revenue growth (YoY) | +69.6% | — |
| Gross margin | 93.4% | — |
| Net margin | −14.4% | — |
| P/E (TTM) | — | — |
| Price / sales | 4.9× | — |
| Net cash | $1.59B | $268.7M |
| Dividend yield | — | — |
| Volatility (60d) | 43.4% | 59.6% |
| Short % of float | 10.5% | 14.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).